AA
SRPT icon

Apriem Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Apriem Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-500
Closed -$31K – 739
2016
Q3 		$31K Sell
500
-5,300
-91% -$160K 0.01% 280
2016
Q2 		$111K Buy
5,800
+1,000
+21% +$18.5K 0.04% 157
2016
Q1 		$94K Buy
+4,800
New +$83.9K 0.04% 143

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Apriem Advisors's SRPT Position: Q4 2016 in Review

Apriem Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2016, closing a stake of 500 shares — an estimated $31K sold.

Apriem Advisors first reported a position in SRPT in Q1 2016 and held it in 3 quarters. The position peaked at $111K in Q2 2016. 177 funds tracked by Wall St. Rank hold SRPT as of Q4 2016.

  • Apriem Advisors reported no remaining Sarepta Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Apriem Advisors sold 500 Sarepta Therapeutics shares in Q4 2016, an estimated $31K.
  • Apriem Advisors first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 3 quarters.
  • Apriem Advisors's Sarepta Therapeutics position peaked at $111K in Q2 2016.
  • 177 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2016.

Based on Apriem Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.